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Responses were assessed in accordance with standardized response criteria by 
the treating physician and reviewed and confirmed by the study center principal 
investigator. Duration of response was determined based on progression, as defined 
per Center for International Blood and Marrow Transplant Research (CIBMTR) criteria, 
as requirement of additional systemic therapy (including corticosteroid doses in excess 
of those used on Day 1) or death. In accordance with CIBMTR criteria, graft-versus-host 
disease (GVHD) flares were not taken into consideration of response. Dose-limiting 
toxicities were defined as any of the following up to and including Day 28: grade ≥3 (per 
Common Terminology Criteria for Adverse Events v4.03 criteria) nonhematologic 
treatment-related toxicity; clinically significant grade ≥3 clinical chemistry abnormality; 
grade 4 neutropenia for >7 days or a ≥90% decrease in absolute neutrophil count from 
baseline related to study treatment; platelet count <10 × 109/L that did not recover after 
2 weeks without transfusion support and with evidence of hypocellularity; and 
secondary graft failure (>95% recipient cells any time after engraftment with no signs of 
relapse, or retransplantation because of secondary neutropenia [<0.5 × 109/L] and/or 
thrombocytopenia [<30 × 109/L]). 
Plasma samples were analyzed for itacitinib using a validated liquid 
chromatography–tandem mass spectrometry assay (Incyte Corporation, Wilmington, 
DE). PK parameters were calculated using standard noncompartmental (model-




For the multiplex assay, test cartridges were primed with samples from each 
patient to test each analyte in a separate channel using their respective antibodies. 
Standard curves were provided by the manufacturer. Replicate values within 10% CV of 
the mean were included. 
Statistical Analysis 
Patients were excluded from the steady state pharmacokinetic (PK) analysis if 
sampling time points were missing, if they missed the last dose before PK assessment, 
or if the time of last dose was not available. For other analyses, cumulative incidence 
functions of nonrelapse-related mortality (NRM) and relapse mortality were estimated 
using Gray's method; patients with relapse-related mortality were treated as competing 
risks, and those without observed mortality were censored at their last date known to be 
alive. Cumulative incidence rates of NRM, relapse-related mortality, and primary 
disease relapse rate at 6 months were estimated with 90% CI. Incidence of secondary 
graft failure, acute graft-versus-host disease flares through Day 100 (defined as 
progression after initial complete response or partial response that required re-
escalation of corticosteroid or other topical/systemic therapy), and chronic graft-versus-
host disease (GVHD) at 6 and 12 months were determined. Cumulative corticosteroid 
dose on Days 28, 56, 100, and 180; frequency of GVHD stages by organ on Days 28, 
56, and 100; and immunophenotyping were calculated with summary statistics. 
GraphPad Prism (San Diego, CA) was used for statistical analysis of the biomarker 
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data; statistical differences between groups were determined using an unpaired t test 






At a median (range) follow-up time of 105.0 (29–827) days for the 200-mg group 
and 136.5 (61–841) days for the 300-mg group, median duration of response was not 
reached for either group (200-mg group 95% CI lower limit, 63 days; 300-mg group 95% 
CI lower limit, 71 days).  
Pharmacokinetics 
 The geometric mean AUC0-τ was higher in patients receiving potent CYP3A4 
inhibitors versus those not receiving CYP3A4 inhibitors or taking a mild inhibitor for both 
200-mg (1.7-fold; 6250 nM•h vs 3720 nM•h, respectively) and 300-mg groups (2.9-fold; 
6720 nM•h vs 2320 nM•h, respectively).  
 Two patients who had stage 4 lower gastrointestinal (GI) GVHD had an area 
under the curve (AUC0-τ) of 2540 nM·h and 18,450 nM·h. This AUC0-τ of 18,450 nM·h 
was approximately 4-fold higher than the geometric mean exposure for all other patients 
(4108 nM·h); this patient was receiving concomitant CYP3A4 inhibitors fluconazole and 
posaconazole. Itacitinib exposures were similar between patients with or without upper 
GI tract GVHD involvement (Supplemental Figure 5). The range of maximum 
concentration (231–1280 nM) and AUC0-τ (4880–9380 nM·h) for patients with liver 
GVHD was similar to the geometric mean itacitinib exposure in all other patients 
(Supplemental Figure 6).  
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 Exposures for patients stratified by the presence or absence of potent CYP3A4 
inhibitors were similar, with a great degree of overlap between patients with and without 
the various types of organ involvement (Supplemental Table 6). Patients receiving 
potent CYP3A4 inhibitors showed an approximate 2-fold increase in itacitinib exposure 
compared with patients who were not receiving CYP3A4 inhibitors. 
Biomarker Analysis 
Mean (SEM) levels of suppression of tumorigenicity 2 (ST2) were significantly 
decreased at Day 56 (159.8 [66.3] vs 363.2 [54.1] ng/mL; P=0.026; n=11) and Day 100 
(80.3 [35.8] vs 363.2 [54.1] ng/mL; P=0.010; n=6) among responders versus baseline 
levels, while no significant changes were observed in the other biomarkers examined for 
either group (Supplemental Table 7). Nonresponders generally had higher levels of 
ST2, tumor necrosis factor receptor 1 (TNFR1), and regenerating islet-derived protein 3 
alpha precursor (REG3A) compared with responders at most time points, but the only 
on-treatment values of significance were at Day 7 for TNFR1 (6.8 [2.1] vs 2.2 [0.2] 
ng/mL; P=0.001), REG3A (39.5 [19.6] vs 11.1 [3.1]; P=0.025) and ST2 (1385 [1011] vs 
263.5 [32.3] ng/mL; P=0.051) where the difference bordered on significance. Only a 
single patient from the nonresponder group was evaluable for biomarker analysis on 




Supplemental Table 1. Response definitions 
Response Definition 
CR • CIBMTR score of 0 in all evaluable organs with no intervening 
additional therapy for an earlier progression, PR, or NR 
VGPR • Skin: no rash, or residual erythematous rash involving <25% of the 
body surface, without bullae (residual faint erythema and 
hyperpigmentation excluded)  
• Liver: total serum bilirubin concentration <2 mg/dL or <25% of 
baseline at enrollment  
• GI tract: tolerating food or enteral feeding, predominantly formed 
stools, no overt gastrointestinal bleeding or abdominal cramping, no 
more than occasional nausea or vomiting 
PR • Improvement in ≥1 organ involved with GVHD symptoms without 
progression in others, with no intervening additional therapy for an 
earlier progression, PR, or NR  
PD • Deterioration in ≥1 organ without any improvement in others 
MR • Improvement in ≥1 organ with deterioration in another organ 
manifesting symptoms of GVHD or development of symptoms of 
GVHD in a new organ 
NR • Absence of any improvement or progression as defined or need of 
secondary therapy (including need to re-escalate steroid dose to 
≥2.5 mg/kg/d of prednisone or methylprednisolone equivalent of 2 
mg/kg/d) 
CR, complete response; MR, mixed response; NR, no response; PD, progressive disease; PR, partial response; and 














Treated, n (%) 14 (100) 15 (93.8) 29 (96.7) 
Treatment duration, median (range), d* 76.0 (5–291) 61.0 (5–817) 70.0 (5–817) 
Discontinued treatment, n (%) 14 (100) 16 (100) 30 (100) 
Adverse event 8 (57.1) 7 (43.8)† 15 (50.0) 
Physician decision 3 (21.4)‡ 5 (31.3)§ 8 (26.7) 
Progressive disease 1 (7.1) 3 (18.8) 4 (13.3) 
Death 2 (14.3) 1 (6.3) 3 (10.0)¶ 
Discontinued from study, n (%) 14 (100) 16 (100) 30 (100) 
Death 9 (64.3) 8 (50.0)† 17 (56.7) 
Study terminated by sponsor‖ 3 (21.4) 7 (43.8) 10 (33.3) 
Withdrawal by patient 2 (14.3) 0 2 (6.7) 
Other 0 1 (6.3) 1 (3.3) 
Dose interruption due to adverse 
events, n (%)* 
8 (57.1) 11 (73.3) 19 (65.5) 
Dose reduction due to adverse events, 
n (%)* 
1 (7.1) 3 (20.0) 4 (13.8) 
* Data are for 29 patients in total because 1 patient in the 300-mg dose group did not receive study drug.  
† One patient randomized to itacitinib 300 mg experienced an adverse event prior to any study treatment and did not 
receive itacitinib (listed as discontinued treatment owing to adverse event) and later died (listed as discontinued from 
study owing to death); this patient was not included in safety and efficacy analyses.   
‡ Reasons include tapering of GVHD medications, not responding to study drug, and progressive disease (n=1, 
each). 
§ Reasons include GVHD symptoms resolved, GVHD skin symptoms worsened, adequate response and patient 
moved out of state, tapered off study medication, and improved GVHD and pancytopenia (n=1, each). 
¶ Primary causes of death included sepsis (n=2) and multi-organ failure (n=1). 
‖ Patients had completed treatment and survival follow-up assessments. 
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Supplemental Table 3. Itacitinib-related TEAEs and infections occurring in >1 
patient  
Itacitinib-related TEAE, n (%) 
Itacitinib 
200 mg, n=14 300 mg, n=15 
Grade 3/4 All grades Grade 3/4 All grades 
Nonhematologic  
Sepsis 1 (7.1) 1 (7.1) 2 (13.3) 2 (13.3) 
Increased ALT 0 1 (7.1) 0 1 (6.7) 
Increased blood creatinine 1 (7.1) 1 (7.1) 0 1 (6.7) 
CMV viremia 0 0 1 (6.7) 2 (13.3) 
Fatigue 0 0 0 2 (13.3) 
Peripheral edema 0 0 0 2 (13.3) 
Hematologic  
Anemia 2 (14.3) 2 (14.3) 3 (20.0) 4 (26.7) 
Decreased platelet count 2 (14.3) 2 (14.3) 3 (20.0) 4 (26.7) 
Thrombocytopenia 1 (7.1) 2 (14.3) 2 (13.3) 3 (20.0) 
Decreased neutrophil count 0 1 (7.1) 2 (13.3) 2 (13.3) 
Neutropenia 0 1 (7.1) 1 (6.7) 2 (13.3) 
Pancytopenia 2 (14.3) 2 (14.3) 0 0 
Decreased WBC count 0 0 1 (6.7) 2 (13.3) 
ALT indicates alanine aminotransferase; CMV, cytomegalovirus; TEAE, treatment-emergent adverse event; and 




Supplemental Table 4. Causes of death on study 
Itacitinib dose Primary cause of death Study day 
Relation to study 
treatment 
200 mg Malignancy relapse 57 NA 
200 mg AE (multi-organ failure) 10 None 
200 mg AE (GVHD, GI bleeding, suspected infection) 88 Related to corticosteroids 
200 mg AE (acute hypoxemic respiratory failure) 114 None 
200 mg Malignancy relapse 498 NA 
200 mg Infection (fungal pneumonia) 192  
200 mg AE (sepsis) 16 Related to corticosteroids 
200 mg AE (acute respiratory distress syndrome and hematochezia) 92 None 
200 mg Sepsis 283 NA 
300 mg Cardiac arrest, sepsis 209 NA 
300 mg AE (multi-organ failure) 11 None 
300 mg AE (multi-organ failure) 35 None 
300 mg AE (sepsis) 6 None 
300 mg Hepatorenal syndrome 115 NA 
300 mg AE (acute respiratory distress syndrome) 103 None 
300 mg AE* (gastrointestinal bleed) 123 None 
NA indicates not applicable. 




Supplemental Table 5. Overall response by organ involvement at enrollment 
 Patients with treatment-naive aGVHD (n=12)* 
Response, n (%) Skin, n=4 Liver, n=0 Upper GI, n=5 Lower GI, n=6 
CR 4 (100.0) 0 4 (80.0) 4 (66.7) 
VGPR 0 0 0 0 
PR 0 0 0 0 
Overall response 4 (100.0) 0 4 (80.0) 4 (66.7) 
 Patients with steroid-refractory aGVHD (n=17)* 
Response, n (%) Skin, n=9 Liver, n=5 Upper GI, n=4 Lower GI, n=11 
CR 1 (11.1) 0 1 (25.0) 2 (18.2) 
VGPR 1 (11.1) 0 0 0 
PR 5 (55.6) 1 (20.0) 1 (25.0) 5 (45.5) 
Overall response 7 (77.8) 1 (20.0) 2 (50.0) 7 (63.6) 
* Each patient could have >1 organ involved at enrollment.  
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Supplemental Table 6. Itacitinib plasma exposures for patients with and 
withoutGVHD organ involvement 
 AUC0–τ, nM·h 
 Upper GI Lower GI Liver 





3320±1180       
(n=8) 
4110±3850           
(n=4) 
3120±1590                 
(n=6) 
4040±2850        
(n=6) 







8150±4900             
(n=9) 
7070±6210          
(n=3) 
7100±4650                
(n=4) 
8270±5390            
(n=8) 
7780±5800                  
(n=9) 
8200±1080    
(n=3) 





Supplemental Table 7. Longitudinal biomarker analysis in responders and nonresponders 
 Responders Nonresponders 
Responder vs 
nonresponder 
Biomarker N Mean, ng/mL (SEM) 
Adjusted P value 
(vs baseline) N 
Mean, ng/mL 
(SEM) 




TNFR1        
Baseline 19 2.6 (0.3) NA 8 3.8 (0.6) NA 0.037* 
Day 7 19 2.2 (0.2) 0.788 6 6.8 (2.1) 0.328 0.001* 
Day 14 19 2.1 (0.2) 0.434 3 2.2 (0.6) 0.913 0.839 
Day 28 19 2.1 (0.2) 0.575 2 1.8 (0.4) 0.891 0.593 
Day 56 11 2.2 (0.3) 0.754 1 1.2 (NA) NA NA 
Day 100 6 2.2 (0.5) 0.929 1 1.9 (NA) NA NA 
REG3A        
Baseline 19 17.4 (6.0) NA 8 85.5 (51.4) NA 0.055 
Day 7 19 11.1 (3.1) 0.751 6 39.5 (19.6) 0.875 0.025* 
Day 14 19 14.0 (4.8) 0.974 3 17.9 (14.1) 0.796 0.773 
Day 28 19 16.6 (4.7) >0.999 2 6.3 (3.8) 0.795 0.493 
Day 56 11 14.2 (2.3) 0.989 1 1.9 (NA) NA NA 
Day 100 6 11.8 (1.6) 0.956 1 4.3 (NA) NA NA 
ST2        
Baseline 19 363.2 (54.1) NA 8 540.8 (182.3) NA 0.225 
Day 7 19 263.5 (32.3) 0.359 6 1385 (1011) 0.736 0.051 
Day 14 19 292.6 (45.6) 0.677 3 194.2 (9.7) 0.996 0.411 
Day 28 19 283.2 (41.2) 0.568 2 244.5 (78.8) 0.999 0.771 
Day 56 11 159.8 (66.3) 0.026* 1 79.3 (NA) NA NA 
Day 100 6 80.3 (35.8) 0.010* 1 185.8 (NA) NA NA 
Trappin-2 (elafin)       
Baseline 18 56.1 (35.3) NA 8 12.0 (3.1) NA 0.418 
Day 7 19 11.9 (3.1) 0.180 6 26.1 (15.4) 0.672 0.168 
Day 14 19 8.3 (1.2) 0.128 3 4.8 (0.9) 0.985 0.281 
Day 28 19 10.8 (1.3) 0.162 2 4.6 (1.4) 0.992 0.140 
Day 56 11 18.7 (7.3) 0.459 1 2.7 (NA) NA NA 
Day 100 6 17.3 (2.7) 0.621 1 6.2 (NA) NA NA 
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NA indicates not applicable. 









(A) Mean platelet counts and (B) mean neutrophil counts while on treatment over time. Error bars indicate SD. QD 
indicates once daily.  
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Supplemental Figure 2. Overall survival 
 
 
Median overall survival was not reached (lower 90% CI limit, 123 days) among patients with treatment-naive aGVHD 




Supplemental Figure 3. Corticosteroid dose by visit in patients treated with 
itacitinib 200 mg or 300 mg 
 
Data shown indicate median (horizontal line), mean (circle), 75th and 25thquartiles (upper and lower box boundaries, 




Supplemental Figure 4. Itacitinib exposure by baseline lower GI stage 
  
Upper and lower box boundaries represent the 75th and 25th percentile, respectively, with the horizontal line within 
the box representing the median. The whiskers extend to a maximum of 1.5 × the interquartile range. Values beyond 
the interquartile range were considered outliers and are indicated by dots in the figure. 
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Supplemental Figure 5. Itacitinib exposure by baseline upper GI stage 
  
 
Upper and lower box boundaries represent the 75th and 25th percentile, respectively, with the horizontal line within 
the box representing the median. The whiskers extend to a maximum of 1.5 × the interquartile range. Values beyond 
the interquartile range were considered outliers and are indicated by dots in the figure.  
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Supplemental Figure 6. Itacitinib exposure by baseline liver stage 
  
 
Upper and lower box boundaries represent the 75th and 25th percentile, respectively, with the horizontal line within 
the box representing the median. The whiskers extend to a maximum of 1.5 × the interquartile range. Values beyond 
the interquartile range were considered outliers and are indicated by dots in the figure.  
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Supplemental Figure 7. Baseline levels of (A) REG3A and (B) ST2 in responders 





Supplemental Figure 8. Correlates with CR to itacitinib treatment and STAT 
phosphorylation among responders 
 
 
Peripheral blood samples from serial time points from baseline through Day 180 were analyzed. (A) Absolute 
peripheral blood MDSC numbers following itacitinib treatment through Day 180 by response. (B) Absolute NK 
numbers following itacitinib treatment through Day 180 by response. (C) NK:MDSC ratio following itacitinib treatment 
through Day 100 by response and sensitivity and specificity analysis for NK:MDSC ratio of >0.31. (D) STAT5 
phosphorylation ratio (Day 28/baseline) following itacitinib treatment by response (n=18 evaluable patients). EOT 
indicates end of treatment; MDSC, myeloid-derived suppressor cell; MFI, mean fluorescence intensity; NK, natural 
killer; pSTAT, phosphorylated STAT; STAT, signal transducer and activator of transcription; and Tx, treatment. NR, 
PD, and PR are explained in Supplemental Table 1. 
*P<0.05; ***P<0.001. 
